• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Lopinavir-ritonavir not associated with clinical benefit in patients with severe COVID-19

byThomas Su,Alex Chanand1 others
April 8, 2020
in Infectious Disease, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial involving adults hospitalized with confirmed SARS-CoV-2 infection, treatment with lopinavir-ritonavir in addition to standard supportive care did not yield appreciable benefit.

2. No significant difference between groups was observed in mortality, viral RNA loads, or duration of detectability.

Evidence Rating Level: 2 (Good)

Study Rundown: The novel coronavirus SARS-Cov-2 is known to cause the respiratory illness Covid-19 in varying degrees of severity, but no therapeutic agents have been demonstrated to be effective in combating coronavirus infections. Lopinavir is an HIV type 1 aspartate protease inhibitor that has shown in vitro activity against both SARS and MERS, but the concomitant use of other drugs, the lack of randomization, and the dependence on historical control groups in previous trials has precluded analysis of its efficacy and safety. This open-label trial involving hospitalized adults with laboratory-confirmed COVID-19 found no significant difference in the time to clinical improvement between the lopinavir-ritonavir and standard-care groups. In addition, mortality and the percentage of patients with detectable viral RNA at various time points were similar between groups. While serious adverse events were less common in the lopinavir-ritonavir group, gastrointestinal adverse events occurred more frequently. Limitations of this study were that a significant percentage of patients in the treatment group were unable to complete the full course of administration and that the overall mortality was nearly twice as high as initially reported by descriptive studies. These findings limit the generalizability of the study’s results as it is possible that a less severely ill population may reap greater benefits from the trial regimen. Future studies involving more heterogeneous populations or different combinations of antiviral agents will continue to guide strategy in addressing this new pandemic.

Click here to read the study in NEJM

Relevant Reading: A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option

In-Depth [randomized controlled trial]: 199 adults hospitalized with Covid-19 in Wuhan, China were individually randomized in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, orally) plus standard care or standard care alone, defined as supplemental oxygen, noninvasive and invasive ventilation, antibiotics, vasopressor support, renal-replacement therapy, and extracorporeal membrane oxygenation as needed. Placebos were not prepared due to the trial’s emergent nature. In the intention-to-treat population, no significant difference in time to clinical improvement was detected between groups (median, 16 days vs. 16 days; hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.85; P=0.09). In the modified intention-to-treat population, there was a small but significant difference in time to clinical improvement (median, 15 days vs. 16 days; hazard ratio, 1.39; 95% CI, 1.00 to 1.91). The time to clinical deterioration was also similar between groups (hazard ratio for clinical deterioration, 1.01; 95% CI, 0.76 to 1.34). These findings were independent of the timing of initiation of treatment (either within 12 days of the onset of symptoms or later). While duration of hospitalization did not vary between groups, lopinavir-ritonavir patients had a shorter stay in the ICU (median, 6 days vs. 11 days; difference, −5 days; 95% CI, −9 to 0). Finally, while low-grade gastrointestinal adverse events were more common in the treatment group, serious adverse events occurred less frequently (20% vs 32%).

RELATED REPORTS

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aspartate protease inhibitorCoronavirusLopinavir-ritonavirSARS-CoV-2
Previous Post

Inhibition of inflammation through interleukin pathway may be protective against anemia

Next Post

#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

RelatedReports

Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

July 26, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection

July 18, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]

August 3, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Heparin in noncritically ill COVID-19 patients [Classics Series]

July 17, 2022
Next Post
#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

#VisualAbstract: Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 In Wuhan, China

AAP recommends disaster preparedness measures for children

Early childhood behaviors and family structure associated with peer victimization

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

Critically ill COVID-19 patients may benefit from convalescent plasma therapy

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
  • Litifilimab associated with reduced disease severity in patients with cutaneous lupus erythematosus
  • Shorter time to surgical repair of macula-off retinal detachment may improve final visual acuity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.